A Unique Case of Spontaneous Pneumomediastinum in a Patient With COVID-19 and Influenza Coinfection

Ramalingam, Sathishkumar; Arora, Harkesh; Gunasekaran, Kulothungan; Muruganandam, Maheswari; Nagaraju, Sivakumar

doi:10.1177/23247096211016228

Cited by 5 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pneumothorax due to barotrauma from ventilation, as well as spontaneous pneumothorax due to damage to the alveolar wall, has been reported with a median duration of nine days since the start of symptoms, with a mortality rate of 36% [ 103 , 114 ]. Spontaneous pneumomediastinum in a non-ventilated patient has also been reported [ 115 ]. An autopsy study showed that massive PE can occur in initially asymptomatic COVID-19 patients [ 103 , 116 ].…”

Section: Reviewmentioning

confidence: 99%

From Emergence to Endemicity: A Comprehensive Review of COVID-19

Naik,

Avula,

Palleti

et al. 2023

Cureus

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), later renamed coronavirus disease 2019 (COVID-19), was first identified in Wuhan, China, in early December 2019. Initially, the China office of the World Health Organization was informed of numerous cases of pneumonia of unidentified etiology in Wuhan, Hubei Province at the end of 2019. This would subsequently result in a global pandemic with millions of confirmed cases of COVID-19 and millions of deaths reported to the WHO. We have analyzed most of the data published since the beginning of the pandemic to compile this comprehensive review of SARS-CoV-2. We looked at the core ideas, such as the etiology, epidemiology, pathogenesis, clinical symptoms, diagnostics, histopathologic findings, consequences, therapies, and vaccines. We have also included the long-term effects and myths associated with some therapeutics of COVID-19. This study presents a comprehensive assessment of the SARS-CoV-2 virology, vaccines, medicines, and significant variants identified during the course of the pandemic. Our review article is intended to provide medical practitioners with a better understanding of the fundamental sciences, clinical treatment, and prevention of COVID-19. As of May 2023, this paper contains the most recent data made accessible.

show abstract

Section: Reviewmentioning

confidence: 99%

From Emergence to Endemicity: A Comprehensive Review of COVID-19

Naik,

Avula,

Palleti

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Pneumothorax due to barotrauma from ventilation as well as spontaneous pneumothorax due to damage to the alveolar wall has been reported with a median duration of nine days since the start of symptoms, with a mortality rate of 36% (103,114). Spontaneous pneumomediastinum in a non-ventilated patient has also been reported (115). In an autopsy study, it was shown that massive PE (pulmonary embolism) can occur in initially asymptomatic COVID-19 patients (103,116).…”

Section: Skinmentioning

confidence: 99%

COVID-19: From Emergence to Endemicity - A Comprehensive Review

Naik,

Avula,

Palleti

et al. 2023

Preprint

View full text Add to dashboard Cite

Severe Acute Respiratory Syndrome Coronavirus - 2 (SARS-CoV-2), later renamed Coronavirus Disease 2019 (COVID-19) was first identified in Wuhan, China, in early December 2019. Initially, the China office of the World Health Organization was informed of numerous cases of pneumonia of unidentified etiology in Wuhan, Hubei Province on December 31, 2019. This would subsequently result in a global pandemic with over 76 million confirmed cases of COVID-19 and 6.9 million deaths reported to the WHO. We have analyzed most of the data published since the beginning of the pandemic to compile this comprehensive review of SARS-CoV-2. We look at the core ideas, such as the etiology, epidemiology, pathogenesis, clinical symptoms, diagnostics, histopathologic findings, consequences, therapies, and vaccines. We have also included the long-term effects and myths associated with some therapeutics of COVID-19. This study comprehensively assesses of the SARS-CoV-2 virology, vaccines, medicines, and significant variants identified during the pandemic. Our review article is intended to provide medical practitioners with a better understanding of the fundamental sciences, clinical treatment, and prevention of COVID-19. As of June 2023, this paper contains the most recent data made accessible.

show abstract

A systematic review of the clinical characteristics of influenza-COVID-19 co-infection

et al. 2023

View full text Add to dashboard Cite

COVID-19 has impacted populations across the globe and has been a major cause of morbidity and mortality. Influenza is another potentially deadly respiratory infection that affects people worldwide. While both of these infections pose major health threats, little is currently understood regarding the clinical aspects of influenza and COVID-19 co-infection. Our objective was to therefore provide a systematic review of the clinical characteristics, treatments, and outcomes for patients who are co-infected with influenza and COVID-19. Our review, which was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, involved searching for literature in seven different databases. Studies were eligible for inclusion if they included at least one co-infected patient, were available in English, and described clinical characteristics for the patients. Data were pooled after extraction. Study quality was assessed using the Joanna Brigg’s Institute Checklists. Searches produced a total of 5096 studies, and of those, 64 were eligible for inclusion. A total of 6086 co-infected patients were included, 54.1% of whom were male; the mean age of patients was 55.9 years (SD = 12.3). 73.6% of cases were of influenza A and 25.1% were influenza B. 15.7% of co-infected patients had a poor outcome (death/deterioration). The most common symptoms were fever, cough, and dyspnea, with the most frequent complications being pneumonia, linear atelectasis, and acute respiratory distress syndrome. Oseltamivir, supplemental oxygen, arbidol, and vasopressors were the most common treatments provided to patients. Having comorbidities, and being unvaccinated for influenza, were shown to be important risk factors. Co-infected patients show symptoms that are similar to those who are infected with COVID-19 or influenza only. However, co-infected patients have been shown to be at an elevated risk for poor outcomes compared to mono-infected COVID-19 patients. Screening for influenza in high-risk COVID-19 patients is recommended. There is also a clear need to improve patient outcomes with more effective treatment regimens, better testing, and higher rates of vaccination.

show abstract

A Unique Case of Spontaneous Pneumomediastinum in a Patient With COVID-19 and Influenza Coinfection

Cited by 5 publications

References 4 publications

From Emergence to Endemicity: A Comprehensive Review of COVID-19

From Emergence to Endemicity: A Comprehensive Review of COVID-19

COVID-19: From Emergence to Endemicity - A Comprehensive Review

A systematic review of the clinical characteristics of influenza-COVID-19 co-infection

Contact Info

Product

Resources

About